What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls

There is evidence of blood-borne miRNA signatures for various human diseases. To dissect the origin of disease-specific miRNA expression in human blood, we separately analyzed the miRNome of different immune cell subtypes, each in lung cancer patients and healthy individuals. Each immune cell type revealed a specific miRNA expression pattern also dependinging on the cell origin, line of defense, and function. The overall expression pattern of each leukocyte subtype showed great similarities between patients and controls. However, for each cell subtype we identified miRNAs that were deregulated in lung cancer patients including hsa-miR-21, a well-known oncomiR associated with poor lung cancer prognosis that was up-regulated in all leukocyte subtype comparisons of cancer versus controls. While the miRNome of cells of the adaptive immune system allowed only a weak separation between patients and controls, cells of the innate immune system allowed perfect or nearly perfect classification. Leukocytes of lung cancer patients show a cancer-specific miRNA expression profile. Our data also show that cancer specific miRNA expression pattern of whole blood samples are not determined by a single cell type. The data indicate that additional blood components, like erythrocytes, platelets, or exosomes might contribute to the disease specificity of a miRNA signature.

[1]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[2]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[3]  Christina Backes,et al.  Toward the blood-borne miRNome of human diseases , 2011, Nature Methods.

[4]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[5]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[6]  W. De,et al.  Prognostic significance of serum miRNA‐21 expression in human non‐small cell lung cancer , 2011, Journal of surgical oncology.

[7]  R. Agami,et al.  MicroRNA regulation by RNA-binding proteins and its implications for cancer , 2011, Nature Reviews Cancer.

[8]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[9]  Allen D. Delaney,et al.  Comprehensive microRNA expression profiling of the hematopoietic hierarchy , 2010, Proceedings of the National Academy of Sciences.

[10]  Marijn T. M. van Jaarsveld,et al.  DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity , 2014, Molecular oncology.

[11]  A. Schetter,et al.  Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancer , 2012, International journal of cancer.

[12]  T. Whiteside Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? , 2013, Cancer Immunology, Immunotherapy.

[13]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.

[14]  Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[15]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[16]  Yi Zhu,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[17]  A. Keller,et al.  MicroRNA expression changes after lung cancer resection , 2012, RNA biology.

[18]  Minoru Kanehisa,et al.  The KEGG database. , 2002, Novartis Foundation symposium.

[19]  G. Collet,et al.  MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[20]  G. Yousef,et al.  Clinical evaluation of microRNA expression profiling in non small cell lung cancer. , 2013, Lung cancer.

[21]  Eckart Meese,et al.  Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. , 2011, Lung cancer.

[22]  Vassilis Georgoulias,et al.  Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. , 2008, Clinical chemistry.

[23]  C. Meyer,et al.  The three main stumbling blocks for anticancer T cells. , 2012, Trends in immunology.

[24]  S. Teichmann,et al.  A HaemAtlas: characterizing gene expression in differentiated human blood cells , 2008, Blood.

[25]  W. Cho OncomiRs: the discovery and progress of microRNAs in cancers , 2007, Molecular Cancer.

[26]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[27]  Lijun Xu,et al.  miR‐150 promotes the proliferation of lung cancer cells by targeting P53 , 2013, FEBS letters.

[28]  Catalin C. Barbacioru,et al.  Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. , 2011, Molecular bioSystems.

[29]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[30]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[31]  N. Rajewsky,et al.  MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb , 2007, Cell.

[32]  Eckart Meese,et al.  Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis , 2011, RNA biology.

[33]  Donavan T. Cheng,et al.  Expression Profiling of Human Immune Cell Subsets Identifies miRNA-mRNA Regulatory Relationships Correlated with Cell Type Specific Expression , 2012, PloS one.

[34]  Christina Backes,et al.  GeneTrail—advanced gene set enrichment analysis , 2007, Nucleic Acids Res..

[35]  Eckart Meese,et al.  miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments , 2009, BMC Cancer.

[36]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[37]  Y. Shu,et al.  MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis , 2011, Journal of Cancer Research and Clinical Oncology.

[38]  Norbert Gretz,et al.  miRWalk - Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes , 2011, J. Biomed. Informatics.

[39]  Monika Belickova,et al.  Differential expression of microRNAs in hematopoietic cell lineages , 2008, European journal of haematology.

[40]  Eckart Meese,et al.  MicroRNAs – Important Molecules in Lung Cancer Research , 2011, Front. Gene..

[41]  S. Safe,et al.  miR-150 Blocks MLL-AF9–Associated Leukemia through Oncogene Repression , 2013, Molecular Cancer Research.

[42]  Peng Zhang,et al.  Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features. , 2013, Oncology reports.